The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute is part of The Ohio State University and one of the 45 National Comprehensive Cancer hospitals. It is named after Arthur G. James, the founder, who desired a cancer hospital in Columbus, Ohio, United States.

There are 306 beds in Ohio State University; Hemat/Onc.

During the past decade, Ohio State University; Hemat/Onc conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 1 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Ohio State University; Hemat/Onc" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator, "Blueprint Medicines Corporation" with 1 trials as a collaborator, "Chugai Pharmaceutical Co." with 1 trials as a collaborator and "Hoffmann-La Roche" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Ohio State University; Hemat/Onc" are "Advanced Solid Tumor" (1 trials), "Cancer" (1 trials), "Non-small Cell Lung Cancer" (1 trials) and "Solid Tumors" (1 trials). Many other conditions were trialed in "Ohio State University; Hemat/Onc" in a lesser frequency.

Most popular intervention types in "Ohio State University; Hemat/Onc" are "Drug" (4 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (2 trials), "Alectinib" (1 trials), "Avelumab" (1 trials), "Carboplatin" (1 trials) and "Chemotherapy" (1 trials). Other intervention names were less common.

The vast majority of trials in "Ohio State University; Hemat/Onc" are 4 trials for "All" genders.

Currently, there are NaN active trials in "Ohio State University; Hemat/Onc". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Ohio State University; Hemat/Onc, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Ohio State University; Hemat/Onc, 2 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".